Agios Pharmaceuticals (AGIO) to Release Quarterly Earnings on Thursday

Agios Pharmaceuticals (NASDAQ:AGIO) is scheduled to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The company had revenue of $8.60 million during the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.51) EPS. On average, analysts expect Agios Pharmaceuticals to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Agios Pharmaceuticals Stock Performance

Shares of NASDAQ AGIO opened at $44.33 on Thursday. The stock has a fifty day moving average price of $44.64 and a two-hundred day moving average price of $41.42. Agios Pharmaceuticals has a 1 year low of $19.80 and a 1 year high of $53.28. The firm has a market cap of $2.52 billion, a P/E ratio of -7.01 and a beta of 0.75.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Leerink Partners downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $60.00 to $56.00 in a report on Friday, September 27th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Raymond James reissued an “outperform” rating and set a $51.00 price objective on shares of Agios Pharmaceuticals in a research note on Thursday, October 10th. Leerink Partnrs cut Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Finally, Scotiabank began coverage on shares of Agios Pharmaceuticals in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $51.00 price objective for the company. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $52.00.

Insider Activity

In other news, CEO Brian Goff sold 11,091 shares of the business’s stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now directly owns 78,792 shares in the company, valued at $3,368,358. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares of the company’s stock, valued at $988,346.74. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Brian Goff sold 11,091 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $42.75, for a total transaction of $474,140.25. Following the transaction, the chief executive officer now owns 78,792 shares in the company, valued at approximately $3,368,358. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 4.93% of the stock is owned by corporate insiders.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.